ADRB2 and Parkinson disease: Recently, β2-adrenoceptors (β2-AR) were suggested as brand novel therapeutic targets in PD, based on their ability to modulate α-synuclein gene expression in human cells and to abrogate neurodegeneration in the MPTP mouse model of PD, and considering the association in the Norwegian population between use of the β2-AR agonist salbutamol and of the β2-AR antagonist propranolol with, respectively, reduced and increased risk of PD [59].